In a groundbreaking development, researchers have concluded the first human clinical trial assessing the efficacy of baricitinib, a drug typically used for rheumatoid arthritis, in treating new-onset type 1 diabetes (Source: Healthline). Baricitinib works by preserving insulin-producing beta cells in the pancreas. This offers a unique approach to managing type 1 diabetes by maintaining the body’s natural insulin production.
Belonging to the Janus kinase inhibitors (JAK inhibitors) class, baricitinib modulates immune system signaling, preventing overactivity that leads to autoimmune conditions. The study, known as the “Baricitinib in New-onset Type 1 Diabetes” (BANDIT) trial, published in the New England Journal of Medicine, enrolled 91 patients diagnosed within 100 days of the trial’s commencement. The participants, averaging 18 years old, were divided into groups receiving either baricitinib or a placebo.
The key focus was on C-peptide levels, indicating natural insulin production. After a 48-week trial period, the baricitinib group exhibited a remarkable 48% increase in median C-peptide levels post-meal compared to the placebo group. This suggests the drug’s potential to preserve insulin production in individuals with type 1 diabetes.
Professor Thomas Kay, MD, PhD, leading the clinical trials, emphasized the importance of initiating treatment soon after diagnosis to protect insulin function before beta cells are irreversibly damaged. The results showcase a paradigm shift from traditional insulin injection therapies that have been the standard for a century.
The study’s findings were deemed “promising” by Dr. Michael Hughes from Stanford University, noting baricitinib’s existing availability, oral administration, and well-tolerated profile as factors making it a potential and accessible option in clinical settings.
Beyond C-peptide levels, researchers examined secondary outcomes, including insulin dose and glycated hemoglobin levels (A1C test), further reinforcing the positive impact of baricitinib on type 1 diabetes management.
While acknowledging the trial’s limitations, such as a small participant pool and observation period, the results open new avenues for treating type 1 diabetes, marking a significant stride in medical research.
Read Also:
